Document Detail


The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review.
MedLine Citation:
PMID:  3525009     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The dopamine agonist bromocriptine has been widely used to facilitate pregnancy in hyperprolactinaemic women, with a success rate of 80% in relevant cases. Neither the inappropriate hyperprolactinaemia consequent upon bromocriptine withdrawal after conception nor the relative hypoprolactinaemia caused by treatment throughout gestation appears to affect adversely the course and outcome of pregnancy or the endocrine status of the fetus. No teratogenic effect of bromocriptine has been evidenced in humans, and no disturbances in the physical, psychomotor, and intellectual development of the offspring have been observed. Pituitary-tumor enlargement during closely supervised pregnancies very rarely leads to severe and irreversible complications; both the re-institution of bromocriptine treatment in the event of tumor enlargement and its preventive use throughout pregnancy have been shown to be effective measures. It is interesting, moreover, that a reduction of hyperprolactinaemia, compared with pregestational levels, may be seen after bromocriptine-facilitated pregnancies.
Authors:
C Weil
Related Documents :
15667449 - Intracerebroventricular injections of prolactin counteract the antagonistic effect of b...
21122599 - A swedish study of midwives' and nurses' experiences when women are diagnosed with a mi...
6718069 - The fetal adrenal gland: lipid distribution with associated intrauterine hypoxia.
205819 - Differential maternal-fetal response to androgenizing luteoma or hyperreactio luteinalis.
12673099 - Selective fetal hypophysectomy in utero: microsurgical technique and comparisons with h...
576229 - Transient bitemporal hemianopsia during pregnancy after treatment of galactorrhea-ameno...
20101849 - Relationship of serum progesterone (p) level the day after human chorionic gonadotropin...
19936969 - Complement activation and pregnancy failure.
9845399 - Foetal outcome in women with inflammatory bowel disease treated during pregnancy with o...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current medical research and opinion     Volume:  10     ISSN:  0300-7995     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  1986  
Date Detail:
Created Date:  1986-09-17     Completed Date:  1986-09-17     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  172-95     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abnormalities, Drug-Induced / etiology
Adenoma / pathology,  surgery
Bromocriptine / adverse effects,  therapeutic use*
Endocrine Glands / drug effects
Female
Humans
Hyperprolactinemia / blood,  drug therapy*
Infant
Infertility, Female / drug therapy*
Pituitary Neoplasms / pathology,  surgery
Pregnancy / drug effects
Pregnancy Complications / chemically induced
Pregnancy Complications, Neoplastic / pathology,  surgery
Prolactin / blood
Risk
Time Factors
Chemical
Reg. No./Substance:
25614-03-3/Bromocriptine; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ultrasound monitored hepatic cryosurgery: longevity study on an animal model.
Next Document:  Distributions of vimentin and desmin filaments in embryonic cardiac muscle cells in culture.